EMPEROR-Preserved: A promise fulfilled

Deepak L Bhatt; Subodh Verma; Bertram Pitt

doi:10.1016/j.cmet.2021.10.011

EMPEROR-Preserved: A promise fulfilled

Cell Metab. 2021 Nov 2;33(11):2099-2103. doi: 10.1016/j.cmet.2021.10.011.

Authors

Deepak L Bhatt¹, Subodh Verma², Bertram Pitt³

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: dlbhattmd@post.harvard.edu.
² Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Departments of Surgery and Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
³ University of Michigan, Ann Arbor, MI, USA.

PMID: 34731652
DOI: 10.1016/j.cmet.2021.10.011

Abstract

Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest unmet needs in medicine. In the EMPEROR-Preserved trial, recently reported in the NEJM, the SGLT2 inhibitor empagliflozin reduced the primary outcome of heart failure hospitalizations and cardiovascular death by 21% in patients with HFpEF. This represents an important breakthrough in the war against heart failure.

Publication types

Comment

MeSH terms

Heart Failure* / drug therapy
Humans
Sodium-Glucose Transporter 2 Inhibitors*
Stroke Volume

Substances

Sodium-Glucose Transporter 2 Inhibitors